These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 29714517)

  • 1. Introduction to the Special Section for Sources of Safety Data and Statistical Strategies for Design and Analysis.
    Zink RC
    Ther Innov Regul Sci; 2018 Mar; 52(2):140. PubMed ID: 29714517
    [No Abstract]   [Full Text] [Related]  

  • 2. Sources of Safety Data and Statistical Strategies for Design and Analysis: Clinical Trials.
    Zink RC; Marchenko O; Sanchez-Kam M; Ma H; Jiang Q
    Ther Innov Regul Sci; 2018 Mar; 52(2):141-158. PubMed ID: 29714519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sources of Safety Data and Statistical Strategies for Design and Analysis: Real World Insights.
    Marchenko O; Russek-Cohen E; Levenson M; Zink RC; Krukas-Hampel MR; Jiang Q
    Ther Innov Regul Sci; 2018 Mar; 52(2):170-186. PubMed ID: 29714518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sources of Safety Data and Statistical Strategies for Design and Analysis: Postmarket Surveillance.
    Izem R; Sanchez-Kam M; Ma H; Zink R; Zhao Y
    Ther Innov Regul Sci; 2018 Mar; 52(2):159-169. PubMed ID: 29714520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing safety signals in large endpoint trials.
    Alemayehu D
    Curr Drug Saf; 2008 May; 3(2):86-90. PubMed ID: 18690986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sources of Safety Data and Statistical Strategies for Design and Analysis: Transforming Data Into Evidence.
    Ma H; Russek-Cohen E; Izem R; Marchenko OV; Jiang Q
    Ther Innov Regul Sci; 2018 Mar; 52(2):187-198. PubMed ID: 29714524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Missing data: warrant for search and capture].
    Torres F; Pontes C
    Med Clin (Barc); 2013 Oct; 141(7):297-9. PubMed ID: 23706686
    [No Abstract]   [Full Text] [Related]  

  • 8. Statistical trial designs and clinical practice: are they compatible?
    Punt CJ
    Onkologie; 2003 Dec; 26(6):518-9. PubMed ID: 14709922
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety Reporting: It Can Enter the 21st Century-If We Let It.
    Seltzer J; Bhattacharyya A
    Ther Innov Regul Sci; 2018 May; 52(3):354-361. PubMed ID: 29714542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Missing data in confirmatory clinical trials.
    Flyer P; Hirman J
    J Biopharm Stat; 2009 Nov; 19(6):969-79. PubMed ID: 20183459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining, monitoring and combining safety information in clinical trials.
    Enas GG; Goldstein DJ
    Stat Med; 1995 May 15-30; 14(9-10):1099-111; discussion 1113-6. PubMed ID: 7569503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How good is "evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs?
    Naci H; Ioannidis JP
    Annu Rev Pharmacol Toxicol; 2015; 55():169-89. PubMed ID: 25149917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the Risk of a Rare But Plausible Complication That Has Not Occurred After n Trials.
    Ho AM; Ho AK; Mizubuti GB; Dion PW
    Anesth Analg; 2018 Nov; 127(5):1259-1263. PubMed ID: 29878940
    [No Abstract]   [Full Text] [Related]  

  • 14. A review of the limitations of statistical analysis of treatment outcomes used in periodontal research.
    Galgut PN
    J Int Acad Periodontol; 2003 Oct; 5(4):92-7. PubMed ID: 14604057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse drug reactions.
    Loke YK
    Br J Clin Pharmacol; 2012 Jun; 73(6):908-11. PubMed ID: 22360319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do multiinstitutional studies represent a higher level of research than single institution studies?
    Naftel DC
    J Heart Lung Transplant; 1996 Mar; 15(3):229-30. PubMed ID: 8777202
    [No Abstract]   [Full Text] [Related]  

  • 17. Guest editors' note: Special issue on subgroup analysis in clinical trials.
    Wang SJ; Dmitrienko A
    J Biopharm Stat; 2014; 24(1):1-3. PubMed ID: 24392974
    [No Abstract]   [Full Text] [Related]  

  • 18. Consider drug efficacy before first-in-human trials.
    Kimmelman J; Federico C
    Nature; 2017 Jan; 542(7639):25-27. PubMed ID: 28150789
    [No Abstract]   [Full Text] [Related]  

  • 19. The credibility of the FDA.
    Blankfield RP
    Eur J Prev Cardiol; 2013 Dec; 20(6):992-4. PubMed ID: 23867140
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical versus statistical considerations in the design and analysis of clinical research.
    Horwitz RI; Singer BH; Makuch RW; Viscoli CM
    J Clin Epidemiol; 1998 Apr; 51(4):305-7. PubMed ID: 9539886
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.